ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA). This intra-articular formulation is… https://t.co/TSeqNVysjb https://t.co/0OVCobGqsp
Dr. John Cush @RheumNow( View Tweet )
In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar. https://t.co/QVbEVvYz7y https://t.co/1Te22NIUGT
Dr. John Cush @RheumNow( View Tweet )
US health expenditures grew from $4.1 trillion in 2020 to $4.5 trillion in 2022 (17.3% incr).
US saved >$400 billion in 2022 by using generic and biosimilar drugs, https://t.co/Z8kS4elyA3 https://t.co/3LopIiQiqZ
Links:
Dr. John Cush @RheumNow( View Tweet )
Impact of biosimilars on biologic drug development pipelines. https://t.co/7kc0UDVPTy https://t.co/bPV3wAc2XY
Dr. John Cush @RheumNow( View Tweet )
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK
Dr. John Cush @RheumNow( View Tweet )
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush @RheumNow( View Tweet )
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/EwplhAPYJH https://t.co/7Vgn2Rtd4f
Dr. John Cush @RheumNow( View Tweet )
Health Disparities in DMARD Use in RA
A UK study shows biological and targeted synthetic DMARD (b/tsDMARDs) use in newly diagnosed rheumatoid arthritis (RA) varies markedly by ethnicity, age and setting - "one-size-fits-all approach" does not apply.
https://t.co/t7O99FM7fQ https://t.co/CtvfblpPUo
Dr. John Cush @RheumNow( View Tweet )
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/RGS2DJgzyS https://t.co/PhqXt0hIzY
Dr. John Cush @RheumNow( View Tweet )
FDA has approved a 4th biosimilar to Stelara - the new agent, ustekinumab-srl (Imuldosa), is indicated for Rx of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Originator Stelara sales in 2023 were nearly $10.86 USD billion globally… https://t.co/MoNBj2UaVH https://t.co/3Tenkfq0KK
Dr. John Cush @RheumNow( View Tweet )
Risk of Uveitis with Spondyloarthritis
A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can… https://t.co/96rRu77Tyl https://t.co/bGHnZ7lCIm
Dr. John Cush @RheumNow( View Tweet )
Dot the "i", Cross the "t" (10.11.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.
Read Article
World renowned faculty delivering state of the art lectures. Early bird registration for RheumNow Live is now open!
https://t.co/Yk8dKDdZie https://t.co/d14Mq2AxlI
Links:
Dr. John Cush @RheumNow( View Tweet )
Appraisal of 2023 ACR RA-ILD guidelines (based on only 3 RCTs). Conditional Recs for MMF, AZA, RTX as 1st-line RA-ILD Rx. W/ RA-ILD progression, options include MMF, RTX, nintedanib, TCZ, CTX, & pirfenidone are conditionally recommended https://t.co/9M3XykPQIi https://t.co/S0TMCsVd4y
Dr. John Cush @RheumNow( View Tweet )
Genomic profiling of 34 ANCA-assoc vasculitis pts w/ glomerulonephritis suggests activity by cytokine-producing CD4+ & CD8+ T cells & potential for ustekinumab. 4 relapsing GN pts Rx w/ UST & CTX +steroids, w/ good responses, improved GFR and BVAS scores… https://t.co/ospA8CJ6JE https://t.co/HbRpXMec0f
Dr. John Cush @RheumNow( View Tweet )
FDA has approved Otulfi (ustekinumab-aauz), a ustekinumab biosimilar for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Otulfi ismade by Fresenius Kabi and Formycon https://t.co/p2h9X0C16W https://t.co/YD0uJSEbaq
Dr. John Cush @RheumNow( View Tweet )
JAMA metaanalysis of psoriasis pts (40 RCTs, 21 438 pts) Rx w/ biologics: a >=90% PASI (skin) response was less likely with older age, prior biologics, higher BMI, and smoking https://t.co/v5EpOpYVYt https://t.co/wXTXP76Emu
Dr. John Cush @RheumNow( View Tweet )
Stop Counting Bugs (10.4.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.
Read Article
Have a a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/wvZYVbVW83 https://t.co/n26xAeU64s
Dr. John Cush @RheumNow( View Tweet )
CORRECTION!! UCB announced the LAUNCH of a new phase 3b BE BOLD trial - this study has no report results as yet. It WILL BE a H2H RCTcomparing bimekizumab & rizankizumab in adult #PsA pts using an ACR50 primary endpoint. Yesterday we incorrectly reported this as a completed… https://t.co/apa6VMuQTi https://t.co/BTpwo6ww7W
Dr. John Cush @RheumNow( View Tweet )
UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv
Dr. John Cush @RheumNow( View Tweet )
Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory… https://t.co/aITAeYuJxv https://t.co/tAPFfshPSs
Dr. John Cush @RheumNow( View Tweet )
In utero exposure to upadacitinib review w/ 128 maternal exposures & known outcomes; 80 from RCTs & 48 Postmarketing Pregs. From RCTs - 54-46% live births, 24-38% spont. abortions, 21-15% elective Ab, 1-2% ectopics from RCTs & Postmarketing. No evidence of teratogenicity… https://t.co/s3VJspI59V https://t.co/tV48sKyF8x
Dr. John Cush @RheumNow( View Tweet )
Pain Relief with JAK Inhibitors or Anti-TNFs ?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
https://t.co/oIgNxBF518 https://t.co/L9g9MJQbQx
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
